COMMUNIQUÉS West-GlobeNewswire

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
07/07/2025
Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today [...]
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
07/07/2025
- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults - KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ( [...]
ONWARD Medical Adds Entrepreneur and Neurotechnology Thought Leader Tim Denison, PhD to its Board of Directors
07/07/2025
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Denison is Professor of Clinical Neurosciences at the University of Oxford and was [...]
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
07/07/2025
First-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany, July 7, 2025 – Eleva [...]
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe
07/07/2025
Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains and create over 600,000 jobs [...]
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
07/07/2025
Webcast to be held Monday, July 7th at 8:00 a.m. ET SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics [...]
Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health
07/07/2025
SHELTON, Conn., July 06, 2025 (GLOBE NEWSWIRE) -- Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EGT Synbio, [...]
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus
04/07/2025
TORONTO, July 04, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“ Spectral” or the “Company” ) (TSX: EDT) , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/07/2025
PARIS, 04 juill. 2025 (GLOBE NEWSWIRE) -- (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
04/07/2025
PARIS, July 04, 2025 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Seule la transparence et la responsabilité peuvent sauver le CERN : une condition essentielle pour mettre fin au gaspillage de milliards et accélérer les innovations médicales vitales
04/07/2025
DALLAS, 04 juill. 2025 (GLOBE NEWSWIRE) -- La Crosetto Foundation for the Reduction of Cancer Deaths, une organisation à but non lucratif agréée, lance un « appel urgent aux membres du Parlement européen et des [...]
The Dermatology Group of Arkansas Welcomes Double Board-Certified Dermatologist to Practice
04/07/2025
Dr. Jessica Pillow Brings Her Expertise to the Skin Care-Driven Little Rock Team LITTLE ROCK, Ark., July 04, 2025 (GLOBE NEWSWIRE) -- The Dermatology Group of Arkansas are thrilled to welcome their newest, double board- [...]
Virbac : Déclaration d'actions et de droits de vote 06/2025
04/07/2025
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 06/2025
04/07/2025
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions
04/07/2025
Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman have joined [...]
Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025
04/07/2025
ORION CORPORATION PRESS RELEASE 4 JULY 2025 at 09.00 EEST Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025 Orion will publish Half-Year Financial Report for January– [...]
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner
04/07/2025
The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of Araris Biotech, from a group of outstanding life science entrepreneurs The founding team is developing a [...]
AB Science : Le masitinib reçoit l'autorisation de la FDA et de l'EMA pour l’etude confirmatoire de phase 3 dans le cancer de la prostate métastatique hormono-resistant
04/07/2025
COMMUNIQUÉ DE PRESSE LE MASITINIB REÇOIT L'AUTORISATION DE LA FDA ET DE L'EMA POUR L’ETUDE CONFIRMATOIRE DE PHASE 3 DANS LE CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT, AVEC UNE SÉLECTION DES PATIENTS BASÉE SUR [...]
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
04/07/2025
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION MOST LIKELY TO [...]

Pages